Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On November 14, 2024, Abeona Therapeutics, Inc. (ABEO) announced financial results for the third quarter of 2024 and provided a business update.</li><li>The company recently announced that the U.S. FDA has accepted the re-submission of the Biologics License Application (BLA) for pz-cel and set a PDUFA target action date of April 29, 2025.</li><li>The acceptance of the BLA by the FDA indicates that the resubmission includes all the necessary information that was found to be deficient in the original BLA filing and we are confident that the company has addressed all the issues identified in the CRL and the pre-license inspection.</li></ul>

On November 14, 2024, Abeona Therapeutics, Inc. (ABEO) announced financial results for the third quarter of 2024 and provided a business update.The company recently announced that the U.S. FDA has accepted the re-submission of the Biologics License Application (BLA) for pz-cel and set a PDUFA target action date of April 29, 2025.The acceptance of the BLA by the FDA indicates that the resubmission includes all the necessary information that was found to be deficient in the original BLA filing and we are confident that the company has addressed all the issues identified in the CRL and the pre-license inspection.

ABEO: FDA Accepts BLA Re-Submission for Pz-cel  PDUFA Date of April 29